keyword
MENU ▼
Read by QxMD icon Read
search

NCCN

keyword
https://www.readbyqxmd.com/read/28442505/overexpressed-fatty-acid-synthase-in-gastrointestinal-stromal-tumors-targeting-a-progression-associated-metabolic-driver-enhances-the-antitumor-effect-of-imatinib
#1
Chien-Feng Li, Fu-Min Fang, Yeng-Yang Chen, Ting-Ting Liu, Ti-Chun Chan, Shih-Chen Yu, Li-Tzong Chen, Hsuan-Ying Huang
Purpose: In gastrointestinal stromal tumors (GISTs), lipid-metabolizing enzymes remain underexplored, including fatty acid synthase (FASN). <p>Experimental Design: Forty GISTs were quantitated for FASN mRNA abundance. FASN immunoexpression was informative in 350 GISTs, including 213 with known KIT/PDGFRA/BRAF genotypes. In imatinib-resistant FASN-overexpressing GIST cells, the roles of overexpressed FASN and FASN-targeting C75 in tumor phenotypes, apoptosis and autophagy, KIT transcription, PI3K/AKT/mTOR activation, and imatinib resistance were analyzed by RNA interference or myristoylated-AKT transfection...
April 25, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28441254/gynecologic-oncologist-perspective-about-esmo-esgo-estro-consensus-conference-on-endometrial-cancer
#2
Polat Dursun, Ali Ayhan
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer was simultaneously published in 3 prestigious journals and is sure to have a huge impact on the clinical practice of gynecologic oncology community and other gynecologic cancer care providers.It is a tremendous report representative of great effort. Hovewer, as practicing gynecologic oncologists, endometrial carcinoma is the most common clinical entity encountered in our routine daily practice; as such, we find some of the report confusing and object to some of its findings, as detailed in this brief report...
May 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28440322/does-mpmri-improve-clinical-criteria-in-selecting-men-with-prostate-cancer-for-active-surveillance
#3
K J Tay, R T Gupta, J Holtz, R K Silverman, E Tsivian, A Schulman, J W Moul, T J Polascik
BACKGROUND: Active surveillance (AS) has excellent short to medium term outcomes in well-selected prostate cancer patients. Traditional biopsy-based selection criteria have been criticized for inaccurate determination of cancer grade and extent. We evaluated the incremental benefit of multiparametric magnetic resonance imaging (mpMRI) in patient selection using various AS criteria. METHODS: We retrospectively evaluated men who received mpMRI before radical prostatectomy between 2011 and 2014...
April 25, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28433642/predicting-non-muscle-invasive-bladder-cancer-recurrence-and-progression-in-a-us-population
#4
Kourosh Ravvaz, Marcus E Walz, John A Weissert, Tracy M Downs
PURPOSE: To assess performance of The European Organization for Research and Treatment of Cancer (EORTC) and Club Urologico Español de Tratamiento Oncologico (CUETO) non-muscle invasive bladder cancer (NMIBC) predictive models compared to current US National Comprehensive Cancer Network (NCCN) treatment guidelines in a US population. MATERIALS AND METHODS: Retrospective analysis using electronic medical records of patients with NMIBC within a multicenter US patient population...
April 19, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28427822/reassessment-of-the-clinical-significance-of-portal-superior-mesenteric-vein-invasion-in-borderline-resectable-pancreatic-cancer
#5
S Hoshimoto, S Hishinuma, H Shirakawa, M Tomikawa, I Ozawa, S Wakamatsu, S Hoshi, N Hoshi, K Hirabayashi, Y Ogata
OBJECTIVE: The principal objective of this study is to clarify the prognostic significance of borderline resectable pancreatic cancer (BRPC). The second objective is to evaluate the prognostic impact of the depth of pathological venous invasion. METHODS: The study included 122 pancreatic cancer patients who underwent curative surgery. All computed tomography scans of the patients were retrospectively interpreted and classified according to the NCCN guidelines, version 1...
April 8, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28423684/prognostic-clinicopathologic-factors-in-carcinoma-of-unknown-primary-origin-a-study-of-106-consecutive-cases
#6
Junjeong Choi, Ji Hae Nahm, Sang Kyum Kim
A heterogeneous group of cancers for which the site of origin remains occult after detailed investigations is defined as carcinomas of unknown primary origin (CUPs). Because patients with CUP have a dismal prognosis, we have analyzed CUPs to highlight the implication of clinicopathologic factors related with patient survival. A total of 106 consecutive cases of CUP were collected. A two-step strategy of immunohistochemistry to assess CUPs according NCCN Guidelines is used to separate carcinomatous tumors and subtype carcinomas...
March 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28417310/telemedicine-and-palliative-care-an-increasing-role-in-supportive-oncology
#7
REVIEW
Brooke Worster, Kristine Swartz
With the emergence of telemedicine as a routine form of care in various venues, the opportunities to use technology to care for the most vulnerable, most ill cancer patients are extremely appealing. Increasingly, evidence supports early integration of palliative care with standard oncologic care, supported by recent NCCN guidelines to increase and improve access to palliative care. This review looks at the use of telemedicine to expand access to palliative care as well as provide better care for patients and families where travel is difficult, if not impossible...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28416124/assessment-of-the-external-validity-of-the-national-comprehensive-cancer-network-and-european-society-for-medical-oncology-guidelines-for-non-small-cell-lung-cancer-in-a-population-of-patients-aged-80-years-and-older
#8
REVIEW
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann
Non-small-cell lung cancer (NSCLC) is a disease of the elderly, who are under-represented in clinical trials. This challenges the external validity of the evidence base for its management and of current guidelines, that we evaluated in a population of older patients. We retrieved randomized clinical trials (RCTs) supporting the guidelines and identified 18 relevant topics. We matched a cohort of NSCLC patients aged older than 80 years from the Moffitt Cancer Center database with the studies' eligibility criteria to check their qualification for at least 2 studies...
March 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28413668/palb2-mutation-in-a-woman-with-bilateral-breast-cancer-a-case-report
#9
Hiroshi Nakagomi, Yosuke Hirotsu, Kenichiro Okimoto, Ikuko Sakamoto, Kenji Amemiya, Satoko Nakagomi, Takeo Kubota, Hitoshi Mochizuki, Masao Omata
Partner and localizer of breast cancer 2 (PALB2) was identified as a moderate-risk gene of breast and pancreas cancer. The present authors previously reported that no PALB2 germline mutations with a deleterious frameshift or stop codons were identified in 155 Japanese patients with breast and/or ovarian cancer who were estimated to be at risk of hereditary cancer, according to the National Comprehensive Cancer Network (NCCN) criteria. In the present study, one patient with a deleterious mutation of PALB2 (c...
April 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28406118/recent-advances-in-the-management-of-renal-cell-carcinoma-a-radiation-oncology-perspective
#10
REVIEW
A A Abdus-Salam, A A Olabumuyi, M A Jimoh
Renal cell carcinoma (RCC) is a rare cancer in developing countries like Nigeria. However, with an increasing understanding of its epidemiology, the increasing availability of trained personnel, improvement in diagnostic facilities, and greater awareness in the populace, an increase in its incidence as was witnessed in developed nations in the last few decades could be safely predicted. This narrative review highlights the international best practices in the multidisciplinary approach to the management of RCC, its diagnosis and treatment, with emphasis on recent advances and radiation treatment...
April 2017: Nigerian Journal of Clinical Practice
https://www.readbyqxmd.com/read/28404765/nccn-news
#11
(no author information available yet)
No abstract text is available yet for this article.
April 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28404761/non-small-cell-lung-cancer-version-5-2017-nccn-clinical-practice-guidelines-in-oncology
#12
David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica Bauman, Lucian R Chirieac, Thomas A D'Amico, Malcolm M DeCamp, Thomas J Dilling, Michael Dobelbower, Robert C Doebele, Ramaswamy Govindan, Matthew A Gubens, Mark Hennon, Leora Horn, Ritsuko Komaki, Rudy P Lackner, Michael Lanuti, Ticiana A Leal, Leah J Leisch, Rogerio Lilenbaum, Jules Lin, Billy W Loo, Renato Martins, Gregory A Otterson, Karen Reckamp, Gregory J Riely, Steven E Schild, Theresa A Shapiro, James Stevenson, Scott J Swanson, Kurt Tauer, Stephen C Yang, Kristina Gregory, Miranda Hughes
This selection from the NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
April 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28404760/the-21-gene-recurrence-score-assay-for-node-positive-early-stage-breast-cancer-and-impact-of-rxponder-trial-on-chemotherapy-decision-making-have-clinicians-already-decided
#13
Jagar Jasem, Christine M Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F Borges, Anthony Elias, Peter Kabos
Background: The 21-gene recurrence score (RS) assay is retrospectively validated for assessing prognosis and benefit from chemotherapy in hormone receptor-positive, early-stage breast cancer (EBC) with low RS. We hypothesized that oncologists have already incorporated the RS assay for decision-making in higher-risk, node-positive disease, despite the lack of prospective data and contrary to NCCN Guideline recommendations. This study provides the first analysis of trends and differences in RS use and therapeutic implications in a population-based data set of patients with node-positive EBC...
April 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28404755/nccn-guidelines-insights-breast-cancer-version-1-2017
#14
William J Gradishar, Benjamin O Anderson, Ron Balassanian, Sarah L Blair, Harold J Burstein, Amy Cyr, Anthony D Elias, William B Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P Goetz, Lori J Goldstein, Steven J Isakoff, Janice Lyons, P Kelly Marcom, Ingrid A Mayer, Beryl McCormick, Meena S Moran, Ruth M O'Regan, Sameer A Patel, Lori J Pierce, Elizabeth C Reed, Kilian E Salerno, Lee S Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H Ward, Dorothy A Shead, Rashmi Kumar
These NCCN Guidelines Insights highlight the important updates/changes to the surgical axillary staging, radiation therapy, and systemic therapy recommendations for hormone receptor-positive disease in the 1.2017 version of the NCCN Guidelines for Breast Cancer. This report summarizes these updates and discusses the rationale behind them. Updates on new drug approvals, not available at press time, can be found in the most recent version of these guidelines at NCCN.org.
April 2017: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/28398274/the-new-nccn-guidelines-for-the-management-of-myelofibrosis
#15
Ruben A Mesa
No abstract text is available yet for this article.
March 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/28395768/what-constitutes-an-unmet-medical-need-in-oncology-an-empirical-evaluation-of-author-usage-in-the-biomedical-literature
#16
Eric Lu, Joseph Shatzel, Florence Shin, Vinay Prasad
The phrase "unmet medical need" has important regulatory implications, but there is no empirical analysis of its real world usage. We sought to determine the annual US incidence, 5-year survival, and number of National Comprehensive Cancer Network (NCCN)-recommended regimens for indications described in the literature as an "unmet medical need." We queried Google Scholar to identify publications where authors used the phrase "unmet medical need" to refer to a specific cancer indication. For each indication, we investigated the annual US incidence, 5-year survival, and number of NCCN recommended regimens...
February 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28395084/the-utility-of-expert-diagnosis-in-surgical-neuropathology-analysis-of-consultations-reviewed-at-5-national-comprehensive-cancer-network-institutions
#17
Janet M Bruner, David N Louis, Roger McLendon, Marc K Rosenblum, W Tad Archambault, Susan Most, Tarik Tihan
The aim of this study was to characterize the type and degree of discrepancies between non-expert and expert diagnoses of CNS tumors to identify the value of consultations in surgical neuropathology. Neuropathology experts from 5 National Comprehensive Cancer Network (NCCN) member institutions participated in the review of 1281 consultations selected based on inclusion criteria. The consultation cases were re-reviewed at the NCCN headquarters to determine concordance with the original diagnoses. Among all consultations, 249 (19...
March 1, 2017: Journal of Neuropathology and Experimental Neurology
https://www.readbyqxmd.com/read/28383420/can-laparoscopic-surgery-be-applied-in-gastric-gastrointestinal-stromal-tumors-located-in-unfavorable-sites-a-study-based-on-the-nccn-guidelines
#18
Chang-Ming Huang, Qing-Feng Chen, Jian-Xian Lin, Mi Lin, Chao-Hui Zheng, Ping Li, Jian-Wei Xie, Jia-Bin Wang, Jun Lu, Qi-Yue Chen, Long-Long Cao, Ru-Hong Tu
This article investigated the feasibility of laparoscopic surgery in unfavorable site gastric gastrointestinal stromal tumors (GISTs).We identified 214 patients who underwent primary gastric GIST resection at our institution (January 2006-December 2014) from a prospectively collected database. These patients were divided into a Favorable group (140 cases) and an Unfavorable group (74 cases) according to the 2014 version of the National Comprehensive Cancer Network Clinical Guidelines (NCCN guidelines).The wedge resection rate of the Favorable group was higher than that of the Unfavorable group, and most procedures were performed laparoscopically (P < 0...
April 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28382095/prognostic-influence-of-bcl2-on-molecular-subtypes-of-breast-cancer
#19
Ki-Tae Hwang, Wonshik Han, Jongjin Kim, Hyeong-Gon Moon, Sohee Oh, Yun Seon Song, Young A Kim, Mee Soo Chang, Dong-Young Noh
PURPOSE: We aimed to reveal the prognostic influence of B-cell CLL/lymphoma 2 (BCL2) on molecular subtypes of breast cancer. METHODS: We analyzed 9,468 patients with primary breast cancer. We classified molecular subtypes according to the National Comprehensive Cancer Network (NCCN) and St. Gallen guidelines, mainly on the basis of the expression of hormonal receptor (HR), human epidermal growth factor receptor 2 (HER2), and Ki-67. RESULTS: Regarding NCCN classification, BCL2 was a strong favorable prognostic factor in the HR(+)/HER2(-) subtype (p<0...
March 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28377484/phase-ib-ii-study-of-safety-efficacy-of-combination-therapy-with-multikinase-vegf-inhibitor-pazopanib-and-mek-inhibitor-trametinib-in-advanced-soft-tissue-sarcoma
#20
Vivek Subbiah, Christian Meyer, Ralph Zinner, Funda Meric-Bernstam, Marianna L Zahurak, Ashley O'Connor, Jason Roszik, Kenna Shaw, Joseph A Ludwig, Razelle Kurzrock, Nilofer A Azad
Purpose: Pazopanib, a multi-receptor tyrosine kinase inhibitor targeting primarily vascular endothelial growth factor receptors 1-3 (VEGFRs1-3), is approved for advanced soft tissue sarcoma and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK inhibitor used for melanoma. We hypothesized that vertical pathway inhibition using a trametinib would synergize with pazopanib in advanced soft tissue sarcoma (STS). <p>Experimental Design: In an open-label, multicenter, investigator-initiated NCCN-sponsored trial, patients with metastatic or advanced STS received pazopanib 800 mg and 2 mg of trametinib continuously for 28-day cycles...
April 4, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
keyword
keyword
30821
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"